Intestinal Failure-Associated Metabolic Bone Diseases and Response to Teriparatide

Abstract

Patients requiring home parenteral nutrition (PN) may develop metabolic bone disease, the etiology of which can be multifactorial. We report a case of significantly low bone mass in a postmenopausal woman with history of short bowel syndrome, renal impairment, and previous radiation exposure who responded to intermittent subcutaneous administration of parathyroid hormone. Her bone mineral density normalized after she completed a course of 18 months of treatment, and a bone isotope scan was negative for skeletal malignancy.

Get full access to this article

View all access options for this article.

References

Haderslev K, Tjellesen L, Haderslev P, Staun M. Assessment of the longitudinal changes in bone mineral density in patients receiving home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2004 ;28:289– 294.

Cohen-Solal M, Baudoin F, Joly K, et al. Osteoporosis in patients on long-term home parenteral nutrition: a longitudinal study. J Bone Miner Res. 2003;18:1989– 1998.

Pironi L, Labate AM, Pertkiewicz M, et al. Prevalence of bone disease in patients on home parenteral nutrition. Clin Nutr. 2002;21:289– 296.

Verhage AH, Cheong WK, Allard JP, Jeejeebhoy KN. Increase in lumbar spine bone mineral content in patients on long-term parenteral nutrition without vitamin D supplementation. JPEN J Parenter Enteral Nutr. 1995;19:421– 436.

de Vernejoul MC, Messing B, Modrowski D, Bielakoff J, Buisine A, Miravet L. Multifactorial low remodeling bone disease during cyclic total parenteral nutrition. J Clin Endocrinol Metab. 1985 ;60:109– 113.

Pironi L, Tjellesen L, De Francisco A, et al. Bone mineral density in patients on home parenteral nutrition: a follow-up study. Clin Nutr. 2004;23:1288– 1302.

National Osteoporosis Foundation. Osteoporosis: impact and overview. Available at: http://www.NationalOsteoporosisFoundation.org. Accessed September 15, 2005.

Iwamoto J, Takeda T, Sato Y. Effects of vitamin K2 on osteoporosis. Curr Pharm Des. 2004 ;10:2557– 2576.

Miki T, Nakatsuka K, Naka H, et al. Effect and safety of intermittent weekly administration of human parathyroid hormone 1–34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment. J Bone Miner Metab. 2004 ;22:569– 576.

10.

Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med. 2001 ;344:1434– 1441.

11.

El-Desouki M, Al-Jurayyan N. Bone mineral density and bone scintigraphy in children and adolescents with osteomalacia. Eur J Nucl Med. 1997;24:202– 205.

12.

Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005 ;16:713– 716.

13.

Shike M, Shils ME, Heller A, et al. Bone disease in prolonged parenteral nutrition: osteopenia without mineralization defect. Am J Clin Nutr. 1986;44:89– 98.

14.

Shike M, Sturtridge WD, Tam CS, et al. A possible role of vitamin D in the genesis of parenteral-nutrition-induced metabolic bone disease. Ann Intern Med. 1981 ;95:560– 568.

15.

Harrison JE, Jeejeebhoy KN, Track NS. The effect of total parenteral nutrition (TPN) on bone mass. In: Coburn JW, Klein GL, eds. Metabolic Bone Disease in Total Parenteral Nutrition. Baltimore, MD: Urban and Schwarzenberg; 1985:53 .

16.

Canada T. Aluminum exposure through parenteral nutrition formulations: mathematical versus clinical relevance. Am J Health Syst Pharm. 2005;62:315– 318.

17.

Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005 ;353:555– 565.